ACSL4 and myocardial infarction: Furthermore, 2‐DG and 3‐BP do not have cell‐specific effects, which can target normal tissue and cause drug‐related liver toxicity.[42] RTZ might be associated with an increase in the risk of myocardial infarction[43] and may target ACSL4 in human arterial smooth muscle cells and macrophages.[44] GalNac, a carbohydrate moiety, can specifically target hepatocytes by binding to the liver‐specific receptor ASGR1/2 with high affinity and can effectively mediate the uptake of siRNAs into hepatocytes.